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Globally, cervical cancer is the secondmost 
common cancer among women, with an estimated 
529 409 new cases and 274 883 deaths reported 
in 2008.[1] Approximately 86% of cases occur in 
developing countries, and represent 13% of all 
cancers affecting women.[1]
In South Africa (SA), cervical cancer is the secondmost frequent 
cancer among all women, with a crude incidence rate of 22.8 
cases per 100 000 women.[1] Current estimates indicate that 5 743 
women are diagnosed with cervical cancer annually; with 3 027 
women dying from the disease annually.[1] Approximately 21% of 
women in the general population are estimated to harbour cervical 
human papillomavirus (HPV) at any time, and 62.8% of invasive 
cervical cancers are attributed to HPV oncogenic types 16 or 18.[1] 
Individuals infected with HIV are at an increased risk for HPV-
related cancers.[2]
Globally, the prevalence of genital warts is high, especially in people 
living with HIV.[3] Though there is little information on incidence, 
genital warts are common among sexually active people and usually 
first occur in adolescence.[3] Genital warts are highly infectious, 
with a transmission rate of 65% within sexual partnerships; despite 
treatment, they can recur in up to 75% of cases.[4] HPV types 6 and 11 
are linked to genital warts, with 20 - 50% of lesions also co-infected 
with high-risk HPV types.[4]
The development of the bivalent vaccine Cervarix 
(GlaxoSmithKline) (against HPV types 16 and 18),[5] and the 
quadrivalent vaccine Gardasil (MSD) (against HPV types 6, 11, 16 
and 18)[6] represents a major breakthrough in the options available 
for the prevention of cervical cancer. Both vaccines have been shown 
to be safe, immunogenic and efficacious.[3,5,6] Although licensed for 
use in both the public and private healthcare sectors in SA, they are 
currently only  available in the private sector.[1]
The quadrivalent Gardasil vaccine (used in the HPV demonstration 
project) is indicated in females (aged 9 - 26 years) for the prevention 
of cervical, vulvar, vaginal and anal cancers, as well as genital warts, 
and in males (aged 9 - 26 years) for the prevention of anal cancers 
and genital warts.[6]
Modelling studies estimate that vaccination of 70% of girls aged 
9 - 12 years against HPV types 16 and 18, will result in a 43% 
reduction in the lifetime risk of cervical cancer.[7] Furthermore, the 
implementation of a strategy combining vaccination of young girls 
with screening programmes for women over 30 years, could lead 
to a 53 - 70% reduction in the lifetime risk of cancer, assuming 
70% coverage for both.[7] At 100% coverage with vaccination alone, 
the reduction in the lifetime risk of cancer will be 61%; with the 
combination of vaccination and screening, this will increase to 75%.[8] 
The World Health Organization has recommended that routine 
HPV vaccination be included in national immunisation programmes.3 
Goldie et al.[8] have suggested that focusing existing resources on 
vaccinating girls, rather than dividing resources between girls and 
boys, is the most cost-effective way of reducing the lifetime risk of 
cancer in resource-constrained environments. In SA, the Extended 
Programme on Immunization (EPI), established in 1995, provides 
free vaccination of children against childhood diseases.[9] The service, 
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Background. Cervical cancer is linked to infection of the cervix by oncogenic human papillomavirus (HPV) subtypes. The quadrivalent 
Gardasil vaccine (against HPV types 6, 11, 16, 18), recommended in girls 9 - 12 years of age, has been shown to be safe, immunogenic and 
efficacious, with minimal or no side-effects.
Aim. To demonstrate the capacity of school health teams to carry out vaccinations within a school environment.
Objectives. To assess the uptake of 3 doses of the vaccine, document lessons learnt and provide recommendations for a national rollout of 
school-based HPV vaccination for learners.
Methods. Female learners (age 9 - 12 years) from 31 primary schools in Nongoma and Ceza districts (KwaZulu-Natal province, South 
Africa) were identified for inclusion in the vaccination programme. The 3 doses of  vaccine were administered by existing school health 
teams. Education and training sessions were held with all stakeholders: provincial departments of health and education; school health teams; 
primary healthcare nurses; hospital doctors and nurses; private practitioners; school principals, teachers and governing bodies; parents; and 
community and traditional leaders.
Results. The overall uptake of the vaccine was found to be high: 99.7%, 97.9% and 97.8% for the first, second and third doses respectively 
(N=963). No adverse events were attributed to the HPV vaccine.
Conclusion. This project demonstrated the successful implementation of HPV vaccination among learners (ages 9 - 12 years) using school 
health teams.
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which is available at public health facilities, targets mainly the under-
6-year age group, however.[9]
For school-going children older than 6 years, the newly revised 
National School Health Policy and Implementation Guidelines intends 
to provide a comprehensive, integrated school health programme, 
as part of the primary healthcare package.[10] School health teams, 
comprising qualified nursing personnel, deliver interventions to 
learners in schools, and ensure that all learners have completed their 
vaccination schedules.[10]
The aim of our project was to demonstrate capacity to carry out 
vaccinations against HPV of female learners within the primary 
school environment, using the existing staff and infrastructure 
resources of the school health teams.
The objectives were to assess the uptake of 3 doses of the vaccine 
and to document lessons learnt, thus to provide recommendations for 
the establishment of HPV vaccination in schools.
Methods
Ethics and consent
Ethics approval for the HPV demonstration project was obtained from 
the institutional Human Research Ethics Committee at the University 
of Cape Town (UCT). Approval to conduct the project in the districts of 
Nongoma and Ceza was given by the KwaZulu-Natal (KZN) Provincial 
Department of Health (DoH). Written informed consent was obtained 
from parents/caregivers of the learners prior to starting vaccination.
Setting
The project was undertaken in the Zululand district of KZN. The 
district has an area of 14 810 km2 and a population of 964 005 
people living in small isolated rural settlements or one of the 6 urban 
areas. [11] The district is characterised by widespread poverty, high HIV 
incidence, and poor access to basic services and facilities.
In consultation with the KZN DoH and Department of Education 
(DoE), it was determined that 1 000 female learners (aged 9 - 12, 
in grades 4 - 5) from 31 schools in the Nongoma and Ceza areas 
(18 in Nongoma and 13 in Ceza) would be vaccinated. The schools 
were chosen based on the number of learners in the schools and 
the proximity of schools to clinics. The vaccination schedule was 
administered at 0, 1 and 6 months, as per the recommended time 
intervals required between doses.
Stakeholder participation
The establishment of the HPV Vaccination Demonstration Project 
Working Group ensured the representation and participation of key 
stakeholders from UKZN, provincial and district Departments of 
Health and Education, and MSD.
The DoE provided the list of schools and the number of learners 
from each school who would participate in the vaccination 
programme.  Meetings were held with the department to discuss the 
content of the communication materials for the learners to ensure 
that it was at the appropriate age, maturity and knowledge levels 
of the learners. Once confirmed and approved, information leaflets 
were translated into isiZulu, the local language. The material was also 
available in English.
Key stakeholders in Nongoma and Ceza were identified during 
visits to the sites prior to commencing vaccination. Information 
sessions were held with principals, teachers, school governing 
bodies, parents, community and religious leaders, traditional leaders, 
traditional healers, school health teams, hospital nurses and doctors, 
and private practitioners. Acceptance of the vaccination programme 
by these key stakeholders was considered necessary before the 
programme could be implemented. The training, educational and 
awareness material was tailored specifically towards the needs of 
these different groups of stakeholders.
Inclusion and exclusion criteria
The following were inclusion criteria for vaccination:
• signed informed consent from parent/caregiver
• learner to be in 9 - 12-year age group, or in grade 4 or 5 at time 
of vaccination
• learner to be afebrile and clinically well
• learner willing to return for further doses.
The following were exclusion criteria:
• no signed informed consent from parent/caregiver available
• learners younger than 9 years of age, and older than 12, at the 
time of vaccination
• learner febrile and/or clinically unwell
• learner unable or unwilling to return for further doses.
Project implementation
Vaccination was performed by the school health teams comprising 
4 staff members: a nursing sister, a registered nurse, and 2 enrolled 
nurses. The role of the nursing sister was to ensure that written 
informed consent from parents/caregivers was in place, as well as 
to perform a general clinical appraisal of the learner (measuring 
temperature, height, weight and mid-arm circumference). The 
registered nurse recorded the data on data collection forms. A follow-
up card containing details of the vaccine, the schedule and date of the 
next dose was given to each learner.
If any learner reported any symptoms of ill-health, no vaccination 
was administered, and the learner was then referred to the nearest 
clinic or hospital. Follow-up measures were established for those 
learners who missed doses who needed to be vaccinated in the 
subsequent 2-week period.
The cold chain for the vaccination programme was reviewed 
and shortcomings identified and managed well in advance of 
the implementation. In this regard, refrigerators and freezers 
were purchased by MSD and donated to the district hospitals in 
Nongoma and Ceza. The vaccination distribution plan was matched 
to the schools list and the number of participating learners. 
The vaccines in cooler boxes with accompanying ice-packs were 
prepared by the pharmacy at the hospital and collected by the 
school health teams on the day of the vaccinations. Included in the 
first vaccine distribution packs were bags containing information 
leaflets on cervical cancer and screening. The quantities of vaccine 
and bags were recorded and reconciled at the end of each day by 
pharmacy staff.
Training and education
Training was provided for all healthcare personnel from the Nongoma 
and Ceza districts, and included the school health teams, primary 
healthcare nurses, hospital nurses (outpatients and paediatric), 
doctors and community health workers.
Awareness, information and education sessions on cervical cancer, 
screening and the HPV demonstration project were conducted 
with school principals, governing bodies and teachers. Thereafter, 
teachers set up meetings with the grade 4 and 5 learners to explain the 
project, and to obtain informed consent from parents, who received 
information leaflets, well in advance of the vaccination date.
Data collection and reporting of adverse events
Multi-level data collection tools for reporting of adverse events 
were developed and reviewed by the project team and relevant 
stakeholders, comprising:
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• observation for 15 minutes post vaccination by school health 
nurses in designated observation areas
• observation by teachers in classroom post vaccination
• follow-up regarding any adverse events, with school health 
teams visiting schools a few days post vaccination
• follow-up of vaccinated learners with school health teams 
carrying out community visits, where feasible
• a telephone number was provided so that MSD could be 
notified immediately regarding any adverse event
• the DoH EPI adverse event reporting protocol, already in 
existence, was also used
• doctors who consulted in the private sector in Nongoma and 
Ceza were notified of the vaccination project, and were asked 
to alert the DoH if called upon to treat any learner experiencing 
side-effects post vaccination.
Linkage to the provincial cervical cancer screening 
programme
The HPV vaccine demonstration project is seen as part of a 
comprehensive cervical cancer prevention and treatment programme 
being planned in KZN. Linkage to the cervical cancer screening 
programme was planned in the following manner: parents and 
learners were provided with educational material about cervical 
cancer, screening and prevention; and female members of the 
community were encouraged to have Pap smears at their local clinics.
Results
Vaccination commenced on 7 March 2011, followed by the second dose 
on 4 May 2011 and the third dose on 17 October 2011. Of the initial 
selection of 1 000 learners, a final total of 963 participated (423 from 
Ceza and 540 from Nongoma). Their ages ranged from 7 to 14 years. 
For this analysis, data for 959 learners were analysed (4 had missing 
data on age). The mean age was 9.88 years, median 10 years and mode 
9 years. The youngest learner was 7 years old and the oldest was 14 
years. Most of the learners were in the age categories 9, 10, 11 and 12 
years. Most (94%) of the learners were from grades 4 (69.5%) and 5 
(24.4%). There were 17 missing values (1.8% of the total). However, 
49 learners (5.1%), who were ineligible owing to age (<9 years or >12 
years) were also vaccinated, and included in the analysis.
Table 1 shows the number of learners who received their first, 
second and third doses of vaccine in each district. A total of 960 
learners (99.7%) received their first dose of vaccine (99.4% in 
Nongoma;100% in Ceza). A total of 943 learners (97.9%) received 
their second dose of vaccine (97.6% in Nongoma; 98.4% in Ceza). 
Table 2. Lessons learnt from the HPV Vaccination Demonstration Project, and recommendations for implementation of HPV 
vaccination among female learners
Lessons learnt from the HPV Vaccination Demonstration Project Recommendations for implementation
Lesson 1: Delivering the HPV vaccine to female learners at school, 
using school health teams, can achieve high coverage levels
A school-based system should be considered for the future 
implementation of HPV vaccination among learners
Lesson 2: Planning in advance is essential to the success of the project Schools and staff should be informed well in advance to prepare, and 
to reschedule important events, if necessary
Lesson 3: School health teams followed up all learners who missed 
doses
Systems should be in place to trace and contact all learners who 
missed their doses to complete their schedule
Lesson 4: Carefully scheduling vaccine requests can help optimise cold 
storage capacity
Develop a system for optimal vaccine storage, transport and delivery, 
so as to maintain the cold chain
Lesson 5: High uptake of the vaccine depends on parental/caregiver 
consent
Provide the means and the opportunity for parents/caregivers 
to receive the information that is necessary for them to provide 
informed consent
Lesson 6: Lists of learners eligible for vaccination were obtained from 
school registers
Lists for the learners eligible for vaccination in schools should be 
obtained from school registers held at the school
Lesson 7: Clear, concise guidance is required to standardise adverse 
event reporting
Provide training and clear guidelines for the consistent recognition 
and reporting of adverse events
Lesson 8: The use of predominantly paper-based vaccine records is a 
barrier to real-time monitoring and evaluation
Electronic methods should be used for data capture on a real-time 
basis
Lesson 9: A participatory approach and simple, visual materials are key 
components of an effective training strategy
Use of simple visual materials, in the appropriate language(s), should 
be used for training
Lesson 10: Using a range of approaches to community outreach is 
important, including educational messages and mass media
Mass media, especially local radio stations, should be used to 
disseminate information about the HPV vaccine, to raise awareness 
and reinforce key messages
Table 1. The number of first, second and third HPV vaccine doses given per district and overall in the demonstration project
First dose given Second dose given Third dose given
District No (%) Yes (%) No (%) Yes (%) No (%) Yes (%)
Ceza (n=423) 0 (0) 423 (100) 7 (1.65) 416 (98.35) 8 (1.91) 411 (98.09)
Nongoma (n=540) 3 (0.55) 537 (99.44) 13 (2.41) 527 (97.59) 13 (2.41) 527 (97.59)
Total (N=963) 3 (0.31) 960 (99.69) 20 (2.08) 943 (97.92) 21 (2.19) 938 (97.81)
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A total of 938 learners (97.8%) received their third dose of vaccine 
(97.6% in Nongoma; 98.1% in Ceza).
Two adverse events were reported. On investigation by the DoH, 
the 2 cases were diagnosed as chicken pox and an abdominal abscess 
respectively; following evaluation, neither was found to be related to 
the HPV vaccine.
Although the initial target was 1 000 learners, 963 learners were 
finally vaccinated as there were challenges in tracking the exact 
numbers of learners in particular ages and grades. Even after 
commencement of the school year, there was still movement of 
learners between schools in the two districts. There was a wide range 
of age categories (7 - 14 years) and grades (2 - 9), despite the strict 
inclusion and exclusion criteria. The vaccination of 49 learners, 
despite being ineligible due to age, was attributed to administrative 
oversights during the enrolment process.
Anthropometric data, not shown in this article, will be reported in 
a separate publication.
Discussion
A total of 963 female learners from 31 schools in Nongoma and Ceza 
participated in the HPV demonstration project. Overall, the uptake 
of the vaccine was high for all 3 doses (99.7%, 97.9% and 97.8% 
respectively). The high uptake of vaccine in this project is comparable 
with the results from other studies worldwide. A 2008 HPV vaccination 
study in Bolivia, which vaccinated 3 900 girls, showed 99.7%, 99.2% 
and 97.1% uptake for doses 1, 2 and 3 respectively.[12] In Uganda, 
the results of the HPV vaccination project held in 2008 - 2009 also 
showed a high uptake; in 2008, 99.6% of 3 459 girls received the first 
dose; and 87.8% completed all 3 doses; while in 2009, 93.2% of 2 385 
girls received their first dose, and 86.3% completed all 3 doses.[13] 
Vaccination coverage in school-based programmes was 82.6% in Peru, 
88.9%  in 2009 in Uganda, and 96.1% in 2009 in Vietnam.[14] In India, a 
campaign approach achieved 77.2 - 87.8%  coverage, whereas monthly 
delivery achieved 68.4 - 83.3% coverage.[14]
Table 2 lists the lessons learnt during the HPV Vaccination 
Demonstration Project, and specific recommendations for the future 
implementation of HPV vaccination among female learners.
Conclusion
The HPV Demonstration Project has shown a high uptake 
of the vaccine, using the delivery model of school health teams 
undertaking the vaccination of learners in schools. The lessons and the 
recommendations from this demonstration project are relevant to the 
plan for a national rollout of school-based HPV vaccination, as part of 
the integrated DoH primary healthcare and school health programmes.
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